| Literature DB >> 23350001 |
Cheikh Sokhna1, Oleg Mediannikov, Florence Fenollar, Hubert Bassene, Georges Diatta, Adama Tall, Jean-François Trape, Michel Drancourt, Didier Raoult.
Abstract
BACKGROUND: In tropical Africa, where the spectrum of the bacterial pathogens that cause fevers is poorly understood and molecular-based diagnostic laboratories are rare, the time lag between test results and patient care is a critical point for treatment of disease. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2013 PMID: 23350001 PMCID: PMC3547848 DOI: 10.1371/journal.pntd.0001999
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Location of Dielmo and Ndiop villages in Senegal, West Africa.
Summary data of the POC laboratory in Dielmo, Senegal.
| Geographic coordinates | Dielmo: 13°43′N;16°24′W Ndiop: 13°41′N;16°22′W |
| Administrative situation | Senegal; Fatick region; Toubacouta rural community |
| Date of beginning of full-time activity | February 2011 |
| Number of tests used | 16 types of freeze-dried mix for real-time PCR; 3 RDT (malaria, dengue fever, influenza) |
| Number of samples studied | 440 |
| Number of positive tests | 80 |
| Total cost of project | 158 670 euro |
Figure 2Health and clinical research station in Dielmo.
A malaria longitudinal prospective study for the long-term investigation of host–parasite associations has been conducted in Dielmo since 1990 and the POC was established in 2011.
Figure 3General scheme of the POC with a list of the pathogens diagnosed.
Figure 4Real-time PCR curves of freshly prepared and lyophilized mixes for the detection of R. felis.
Primers and probes used in the study.
| Forward (F) and reverse (R) primers and probes (P) for screening samples | Forward (F) and reverse (R) primers and probes (P) for confirmation of positive samples | ||||||||
| Organism | Gene | Primers (5′-3′) and probes (5′-6-FAM – TAMRA -3′) | Ref | Organism | Gene | Primers (5′-3′) and probes (5′-6-FAM – TAMRA -3′) | Ref | ||
|
|
| FRP |
|
|
| RC0338 (1029) | FRP |
|
|
|
| Hypothetical protein gene RC0743 | FRP |
| This study | |||||
|
| spoT15-dam2 intergenic spacer | FRP |
| This study | |||||
|
|
| FRP |
|
|
|
| FRP |
|
|
|
| Hypothetical protein gene 01310 | FRP |
| This study | |||||
|
| 16S rDNA | FRP |
|
|
|
| FR |
|
|
|
| Spacer IS1111 | FRP |
|
|
| Spacer IS30a | FRP |
|
|
|
| 16S-23S internal transcribed spacer ITS2) | FRP |
|
|
| 16S-23S internal transcribed spacer (ITS3) | FRP |
|
|
|
| yopP | FRP |
|
| |||||
|
| WiSP family protein (WHI3) | FRP |
|
|
| WiSP family protein (WHI2) | FRP |
|
|
- PCR coupled by sequencing, performed in Marseille only.
Figure 5Point-of-Care laboratory implemented in Dielmo village, showing the DNA extraction and mix preparation materials.
Comparison between the molecular assays performed in Marseille and in Dielmo.
| Number of positive / Number of tested | Sensitivity | Specificity | Positive predictive value | Negative predictive value | |||
| Marseille | Dielmo | Discrepancies between both | of on-field POC compared to assays performed in Marseille as gold standard | ||||
|
| 28/440 | 30/440 | 2 | 100% | 99.5% | 93.5% | 100% |
|
| 0/440 | 0/440 | 0 | NA | 100% | NA | 100% |
|
| 0/440 | 0/440 | 0 | NA | 100% | NA | 100% |
|
| 2/440 | 2/440 | 0 | 100% | 100% | 100% | 100% |
|
| 1/440 | 1/440 | 0 | 100% | 100% | 100% | 100% |
|
| 23/440 | 23/440 | 0 | 100% | 100% | 100% | 100% |
|
| 4/440 | Not done | NA | NA | NA | NA | NA |
|
| 35/440 | 35/440 | 4 | 94.3% | 99.5% | 94.3% | 99.5% |
The sensitivity, specificity, positive predictive value, and negative predictive value of on-field Point-Of-Care (POC) were compared to molecular assays performed in Marseille as gold standard.
Two patients concluded as positive in Dielmo were concluded as negative in Marseille.
Two patients concluded as positive in Dielmo were concluded as negative in Marseille and two patients concluded as negative in Dielmo were concluded as positive in Marseille.
NA: Not available.
The treatment of patients included in the study (440 samples).
| Disease | Number of cases | Treatment |
|
| 54 | Combination therapy |
|
| 30 | 5 days of 200 mg per day of doxycycline |
|
| 35 | 5 days of 200 mg per day of doxycycline |
|
| 19 | 5 days of 200 mg per day of doxycycline |
|
| 2 | 15 days of 200 mg per day of doxycycline |
|
| 1 | 15 days of 200 mg per day of doxycycline |